Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (584)	9/3/2002 2:27:12 PM
From: nigel bates	Respond to of 2240

Northwest Bio. up for sale - Message 17947253

To: nigel bates who wrote (584)	12/23/2002 7:44:01 AM
From: nigel bates	Respond to of 2240

(Eos) I'm assuming this is a MEDX Mab... SOUTH SAN FRANCISCO, Calif., Dec. 23 /PRNewswire/ -- Eos Biotechnology today announced the filing of an Investigational New Drug Application (IND) for its therapeutic antibody, Eos200-4. The candidate has been shown to inhibit angiogenesis, the formation of new blood vessels, using in vitro and in vivo models. The role of the molecular target for Eos200-4 in angiogenesis was discovered and developed using Eos' internal genome wide target identification and validation capabilities. The mechanism of action of Eos200-4 is distinct from other anti-angiogenic candidates in clinical trials. The therapeutic antibody works by inhibiting the interaction between activated endothelial cells and their extra-cellular environment, a pivotal step needed for the formation of new, tumor-sustaining blood vessels. The specific endothelial cell surface receptor blocked by Eos200-4, called alpha 5 beta 1 integrin, is required for all angiogenesis, independent of which pro-angiogenic factors are being secreted by tumors. It may be a final critical pathway in the process of angiogenesis. "Eos was founded in 1997 to capitalize on the wealth of information being generated by the Human Genome Project and apply our own genome-wide approach to drug discovery and development. We are delighted to be filing our first IND for a therapeutic antibody based on this approach," said David Martin, CEO, Eos Biotechnology. "In less than five years, we have created an integrated process to rapidly identify and validate therapeutic targets and to develop and evaluate antibodies to them. We currently have a significant pipeline of important product candidates moving from research activities to development." The changing gene activity pattern of the target for Eos200-4 in angiogenesis was detected using the company's proprietary human genome-wide DNA array platform, Hu03. Data from Eos' custom-developed arrays and integrated discovery process were enhanced by independent research from Dr. Judy Varner's laboratory at the University of California at San Diego. Dr. Varner's laboratory continues to pursue studies of this molecule with support, in part, from Eos. "This function-blocking monoclonal antibody has effectively prevented angiogenesis in animal models and has considerable therapeutic potential for a broad range of solid tumors, as well as other medical conditions, such as eye diseases, where new vessel formation causes damage," said Barbara Finck, V.P., Clinical Development, Eos Biotechnology. Eos has used its discovery process to identify hundreds of other targets with novel utility and currently has approximately 30 of these in its therapeutic antibody pipeline. These antibodies target a number of cancers, including prostate, lung, colon, ovarian and breast cancers. Eos intends to introduce antibodies attacking these targets into pre-clinical and clinical development over the next 2 years on its own or in collaboration with other biopharmaceutical companies. About Eos: Eos is privately held biotechnology company based in South San Francisco. Using its proprietary, leading-edge genomic technologies and best-of-breed research tools, the company has developed an integrated approach for identifying novel disease targets and developing highly specific antibodies against them. The company's first candidate, Eos200-4, is directed against a cellular target molecule identified by the company's proprietary genomics platform. Eos has a pipeline of over 30 other therapeutic targets and in many cases, cognate antibodies rapidly moving towards the clinic. Eos expects to continue to develop some of these outright and others in partnership with biopharmaceutical companies.